1. patients with exclusion criteria to the corimuno-19 cohort. 2. respiratory failure requiring non invasive or mechanical ventilation 3. patients requiring intensive care 4. do-not-resuscitate order (dnr order) 5. known hypersensitivity to sarilumab or to any of their excipients. 6. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation 7. known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation 8. pregnancy or breastfeeding 9. current documented bacterial infection. 10. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n

1. patients with exclusion criteria to the corimuno-19 cohort. 2. respiratory failure requiring non invasive or mechanical ventilation 3. patients requiring intensive care 4. do-not-resuscitate order (dnr order) 5. known hypersensitivity to sarilumab or to any of their excipients. 6. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation 7. known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation 8. pregnancy or breastfeeding 9. current documented bacterial infection. 10. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n

patients with exclusion criteria to the corimuno-19 cohort. respiratory failure requiring non invasive or mechanical ventilation patients requiring intensive care do-not-resuscitate order (dnr order) known hypersensitivity to sarilumab or to any of their excipients. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation pregnancy or breastfeeding current documented bacterial infection. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: absolute neutrophil count (anc) ≤ 1.0 x 109/l haemoglobin level: no limitation platelets (plt) < 50 g /l sgot or sgpt > 5n

patients with exclusion criteria to the corimuno-19 cohort. respiratory failure requiring non invasive or mechanical ventilation patients requiring intensive care do-not-resuscitate order (dnr order) known hypersensitivity to sarilumab or to any of their excipients. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation pregnancy or breastfeeding current documented bacterial infection. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: absolute neutrophil count (anc) ≤ 1.0 x 109/l haemoglobin level: no limitation platelets (plt) < 50 g /l sgot or sgpt > 5n

1. patients with exclusion criteria to the corimuno-19 cohort. 2. respiratory failure requiring non invasive or mechanical ventilation 3. patients requiring intensive care 4. do-not-resuscitate order (dnr order) 5. known hypersensitivity to sarilumab or to any of their excipients. 6. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation 7. known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation 8. pregnancy or breastfeeding 9. current documented bacterial infection. 10. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - absolute neutrophil count (anc) ≤ 1.0 x 109/l - haemoglobin level: no limitation - platelets (plt) < 50 g /l - sgot or sgpt > 5n

1. patients with exclusion criteria to the corimuno-19 cohort. 2. respiratory failure requiring non invasive or mechanical ventilation 3. patients requiring intensive care 4. do-not-resuscitate order (dnr order) 5. known hypersensitivity to sarilumab or to any of their excipients. 6. known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, g6pd deficiency and qt prolongation 7. known contra-indication to azithromycin: including hypersensitivity/allergy and qt prolongation 8. pregnancy or breastfeeding 9. current documented bacterial infection. 10. patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - absolute neutrophil count (anc) ≤ 1.0 x 109/l - haemoglobin level: no limitation - platelets (plt) < 50 g /l - sgot or sgpt > 5n